The Zhitong Finance App learned that Cansino Biotech (06185) once fell nearly 8%. As of press release, it fell 6.22% to HK$27.14, with a turnover of HK$2.044,400.

According to the news, US stock Modena plummeted by more than 17% overnight. The phase III clinical trial data for the personalized melanoma vaccine jointly developed with Merck was unexpectedly leaked ahead of schedule. The results fell short of the high expectations formed by the market earlier this year. In August of this year, Modena announced that this customized vaccine, if used in combination with Merck's best-selling drug Keytruda, can significantly reduce the risk of recurrence of this fatal tumor and has clinical significance.

According to reports, Cansino has already built an mRNA development and preparation platform. Cansino Shanghai, a subsidiary of the company, previously signed a cooperative framework agreement with Deputh Biotech to jointly develop personalized mRNA cancer vaccines. Cansino provides mRNA delivery and formulation capabilities, and Depus provides a platform for the discovery and design of new AI antigens.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.